News | PET Imaging | January 25, 2017

Researchers use radiotracer that binds to mature olfactory sensory neurons to quantify neuronal populations

January 25, 2017 — In work published this week in the Journal of Clinical Investigation (JCI), a team led by Jacob Hooker at Harvard Medical School assessed GV1-57, a radiotracer that specifically binds to mature olfactory sensory neurons, as an approach for quantifying neuronal populations with positron emission tomography (PET) imaging.

Olfactory neurons in the nasal cavity are the primary source of our sense of smell. Unlike many types of neurons, olfactory neurons are continuously generated throughout the adult lifespan. This uniquely high rate of neuronal birth and death makes olfactory neurons particularly sensitive to the detrimental effects of progressive neurodevelopmental and neurodegenerative disease. In Alzheimer's disease and Parkinson's disease, loss of the sense of smell often precedes classical symptoms of cognitive or motor dysfunction. Therefore, a technique that is able to non-invasively quantify the olfactory neuron population could provide important insights related to the diagnosis and progression of neurodevelopmental and neurodegenerative diseases.

Using GV1-57, researchers were able to detect neuron generation during rodent postnatal development as well as neuron degeneration in rodent models of aging and neurodegenerative disease. In an additional proof-of-concept experiment, they showed that GV1-57 maintained saturable binding in non-human primate nasal cavity, suggesting that this radiotracer may be useful for evaluating neurological disease in clinical settings.

For more information: www.jci.org

Van de Bittner, G.C., Riley, M.M., Cao, L., Ehses, J., et al. "Nasal neuron PET imaging quantifies neuron generation and degeneration," The Journal of Clinical Invesigation. Published Jan. 23, 2017. doi:10.1172/JCI89162


Related Content

News | Radiopharmaceuticals and Tracers

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
News | Molecular Imaging

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 21, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time February 21, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 14, 2024 — PanTera, the Belgian joint venture created by IBA and SCK CEN to secure large-scale production of ...

Time February 14, 2024
arrow
News | Quality Assurance (QA)

February 12, 2024 — IBA, a world leader in particle accelerator technology and a world-leading provider of dosimetry and ...

Time February 12, 2024
arrow
News | Magnetic Resonance Imaging (MRI)

February 9, 2024 — Multiple sclerosis (MS) is a neurological disease that usually leads to permanent disabilities. It ...

Time February 09, 2024
arrow
News | PET Imaging

February 9, 2024 — A novel PET imaging technique can noninvasively detect active inflammation in the body before ...

Time February 09, 2024
arrow
News | SNMMI

February 6, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2024 SNMMI Mid-Winter Meeting ...

Time February 06, 2024
arrow
News | FDA

January 23, 2024 — Siemens Healthineers announces the Food and Drug Administration (FDA) clearance of syngo Virtual ...

Time January 23, 2024
arrow
Subscribe Now